SCHEMBL5353750

SCHEMBL5353750

Nc1cccc(-c2nc3c(Nc4cccc(Cl)c4)ncnc3o2)c1

nearest known ligand 0.55

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
EGFR P00533 15/20 0.55
CDK1 P06493 5/20 0.55
ABL1 P00519 5/20 0.55
PRKCA P17252 2/20 0.55
CAMK2D Q13557 1/20 0.53
ERBB2 P04626 1/20 0.50
TTBK1 Q5TCY1 1/20 0.48
TTBK2 Q6IQ55 1/20 0.48
SRC P12931 1/20 0.46
FADS1 O60427 1/20 0.44
LCK P06239 1/20 0.44
CCNB2 O95067 2/20 0.43
CCNB1 P14635 2/20 0.43
CCNB3 Q8WWL7 2/20 0.43
ABL2 P42684 2/20 0.43
LMNA P02545 1/20 0.42
TP53 P04637 1/20 0.42
THRB P10828 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5785011 0.90 EGFR (0.54) EGFRCDK1ABL1PRKCACAMK2D
Hydrochloric Acid SCHEMBL5351366 0.89 EGFR (0.53) EGFRCDK1ABL1PRKCACAMK2D
Hydrochloric Acid SCHEMBL5350968 0.89 EGFR (0.53) EGFRCDK1ABL1PRKCACAMK2D
SCHEMBL5361357 0.87 TTBK1 (0.48) EGFRCDK1ABL1PRKCATTBK1
SCHEMBL5351369 0.83 EGFR (0.59) EGFRSRC
SCHEMBL14355887 0.81 NPC1 (0.46) EGFRCDK1ABL1PRKCATP53
SCHEMBL5358394 0.80 EGFR (0.56) EGFRTTBK1TTBK2SRC
SCHEMBL4742040 0.79 EGFR (0.49) EGFRCDK1ERBB2TTBK1TTBK2
SCHEMBL5362671 0.79 RET (0.47) EGFRTTBK1LMNA
SCHEMBL5348597 0.76 TTBK1 (0.49) EGFRTTBK1TTBK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7294633-B2 Oxazolo-and furopyrimidines and their use in medicaments against tumors NOVARTIS AG (CH) 2007-11-13 US claimed
EP-1390371-B1 OXAZOLO-AND FUROPYRIMIDINES AND THEIR USE IN MEDICAMENTS AGAINST TUMORS NOVARTIS AG (CH) 2006-03-08 EP claimed
US-20040152892-A1 Oxazolo-and furopyrimidines and their use in medicaments against tumors NOVARTIS AG (CH) 2004-08-05 US claimed
EP-1390371-A1 OXAZOLO-AND FUROPYRIMIDINES AND THEIR USE IN MEDICAMENTS AGAINST TUMORS Novartis AG (CH) 2004-02-25 EP claimed
WO-2002092603-A1 OXAZOLO-AND FUROPYRIMIDINES AND THEIR USE IN MEDICAMENTS AGAINST TUMORS NOVARTIS AG (CH) 2002-11-21 WO claimed
US-7294633-B2 Oxazolo-and furopyrimidines and their use in medicaments against tumors NOVARTIS AG (CH) 2007-11-13 US disclosed
EP-1390371-A1 OXAZOLO-AND FUROPYRIMIDINES AND THEIR USE IN MEDICAMENTS AGAINST TUMORS Novartis AG (CH) 2004-02-25 EP disclosed
WO-2002092603-A1 OXAZOLO-AND FUROPYRIMIDINES AND THEIR USE IN MEDICAMENTS AGAINST TUMORS NOVARTIS AG (CH) 2002-11-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040152892-A1 Oxazolo-and furopyrimidines and their use in medicaments against tumors DPYD, COXFA4L2, MSH2 EGFR 1321/4885CDK1 644/4885ABL1 476/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.